Facile Synthesis of 5- to 7-Membered Benzolactam Compounds via Strongly Facilitated Electrophilic Aromtic Substitution Reaction†
摘要:
We employed our system to activate aromatic ring-tethered carbamate compounds with trifluoromethanesulfonic acid to obtain benzolactams with 5- to 7-membered rings, and examined the substrate scope and limitations of this activation method. In 5-membered ring formation, a halogen group on the aromatic ring did not greatly affect the reaction yield, but other electron-donating groups inhibited the cyclization reaction, and various side-reactions occurred. In 7-membered ring formation, eletron-donating groups on aromatic ring promoted the cyclization reaction, but cyclization of electron-deficient aromatic rings did not proceed well. The 6-membered ring formation reaction showed the greatest substrate generality.
Dimethylamine as a Substrate in Hydroaminoalkylation Reactions
作者:Jens Bielefeld、Sven Doye
DOI:10.1002/anie.201708959
日期:2017.11.20
Size matters: For the first time since catalytic hydroaminoalkylation chemistry started 37 years ago, dimethylamine can efficiently be added to alkenes using an inexpensive and easilyobtainable Ti catalyst. The size of the flask determines whether the reaction gives monohydroaminoalkylation or dihydroaminoalkylation.
[DE] 11 beta -HALOGEN-7 alpha -SUBSTITUIERTE-ESTRATRIENE, VERFAHREN ZUR HERSTELLUNG PHARMAZEUTISCHER PRÄPARATE, DIE DIESE 11 beta -HALOGEN-7 alpha -SUBSTITUIERTE-ESTRATRIENE ENTHALTEN, SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN<br/>[EN] 11 beta -HALOGEN-7 alpha -SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11 beta -HALOGEN-7 alpha -SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS<br/>[FR] ESTRATRIENES 11 beta -HALOGENE-7 alpha -SUBSTITUES, PROCEDE DE PREPARATION DE PREPARATIONS PHARMACEUTIQUES, QUI CONTIENNENT LESDITS ESTRATRIENES 11 beta -HALOGENE-7 alpha -SUBSTITUES ET LEUR UTILISATION POUR PREPARER DES MEDICAMENTS
申请人:SCHERING AKTIENGESELLSCHAFT
公开号:WO1999033855A1
公开(公告)日:1999-07-08
(DE) Die vorliegende Erfindung beschreibt die neuen 11$g(b)-Halogen-7$g(a)-substituierten-Estratriene der allgemeinen Formel (I), worin R11 ein Fluor- oder Chloratom ist und die anderen Substituenten die in der Beschreibung näher erläuterten Bedeutungen haben. Die Verbindungen verfügen über antiestrogene oder gewebeselektive estrogene Eigenschaften und sind zur Herstellung von Arzneimitteln geeignet.(EN) The invention relates to novel 11$g(b)-halogen-7$g(a)-substituted estratrienes of formula (I), wherein R11 is a fluorine or chlorine atom and the other substituents have the meanings given in the description. The inventive compounds have anti-estrogen or tissue selective estrogenic characteristics and are suitable for producing medicaments.(FR) L'invention concerne de nouveaux estratriènes 11$g(b)-halogène-7$g(a)-substitués de la formule générale (I) dans laquelle R11 désigne un atome de fluor ou de chlore et les autres substituants ont les significations mentionnées dans la description. Ces composés présentent des propriétés à action anti-oestrogène ou oestrogène à sélectivité tissulaire et s'utilisent pour préparer des médicaments.
PRODUCTION OF AMINES VIA A HYDROAMINOMETHYLATION REACTION
申请人:Universität Wien
公开号:EP3569593A1
公开(公告)日:2019-11-20
Provided is a process for producing an amine via a hydroaminomethylation reaction of a non-aromatic C-C double bond or C-C triple bond, said process comprising
a step of reacting a compound comprising a non-aromatic C-C double bond or C-C triple bond with a reactive component which is obtainable by combining an aminal with an acidic medium comprising trifluoroacetic acid,
wherein the aminal contains two amino groups independently selected from a secondary and a tertiary amino group that are linked by a methylene group, and at least one of the amino groups carries a hydrogen atom at a carbon atom bound in α-position to its nitrogen atom.
Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.